why choose us

300×250 Ad Slot

Research Article: Treatment patterns and outcomes of patients with a diagnosis of metastatic pancreatic adenocarcinoma in the United States, 2019–2024

Date Published: 2026-07-20

Abstract:
Approximately half of patients with pancreatic cancer present with metastatic disease at diagnosis, for whom 5?year survival remains ~3%. This retrospective study assessed treatment patterns, characteristics associated with first-line (1L) regimen selection, and real-world survival and treatment outcomes in US patients with metastatic pancreatic adenocarcinoma (mPAC). US adults newly diagnosed with mPAC between 1 January 2019 and 1 August 2024 from the electronic health record-derived Flatiron Health Research Database were included. Treatment patterns across the first three lines of therapy were summarized among patients who initiated systemic therapy within 180 days of metastatic diagnosis. Associations between baseline characteristics and 1L regimen selection (across multiple regimen categories) were evaluated using multinomial logistic regression. Overall survival (OS) and time-to-treatment discontinuation (TTD) were assessed using standard survival methods. Among 9,439 patients with mPAC, 6,279 initiated 1L systemic therapy. The most common 1L regimens were gemcitabine plus nab-paclitaxel (Gem-Nab; 41.5%) and folinic acid (leucovorin), fluorouracil (FU), irinotecan, and oxaliplatin (FOLFIRINOX) (36.3%). Mean time to 1L initiation after metastatic diagnosis was 26.9 days. Patients receiving 1L FOLFIRINOX were generally younger, more frequently had baseline Eastern Cooperative Oncology Group performance status 0 or 1, more often presented with de novo metastatic disease, had higher socioeconomic indicators, and were more likely to be treated in academic centers compared with patients receiving Gem-Nab. Overall, 33.5% of patients did not receive systemic therapy within 180 days of metastatic diagnosis. Median OS was longer among patients treated with FOLFIRINOX than among those treated with Gem-Nab [10.7 vs 7.6 months; adjusted hazard ratio (HR), 0.47; 95% confidence interval (CI), 0.43–0.51; P < 0.001]. Median TTD was also longer for FOLFIRINOX compared with Gem-Nab (4.7 vs 3.4 months). Among treated patients, clinical and sociodemographic factors strongly influenced regimen selection, and FOLFIRINOX use was associated with longer survival and treatment persistence than Gem-Nab; although these findings should be interpreted as associative given the substantial differences in patient characteristics between treatment groups. Conversely, one-third of patients did not initiate systemic therapy within 180 days of metastatic diagnosis, which may reflect unmet need or gaps in access to care.

Introduction:
Approximately half of patients with pancreatic cancer present with metastatic disease at diagnosis, for whom 5?year survival remains ~3%. This retrospective study assessed treatment patterns, characteristics associated with first-line (1L) regimen selection, and real-world survival and treatment outcomes in US patients with metastatic pancreatic adenocarcinoma (mPAC).

Read more

300×250 Ad Slot